MRK vs BMY Stock Comparison

MRK

Merck & Co., Inc.

$119.63

BMY

Bristol-Myers Squibb Company

$58.54

Head-to-Head Comparison

Metric	MRK	BMY
Market Cap	$235.0B	$115.0B
P/E Ratio	12.0	8.0
Div Yield	N/A	N/A
Sector	Healthcare	Healthcare
Beta	0.26	0.27
Revenue	N/A	N/A
Net Income	N/A	N/A
EPS	N/A	N/A

AI Comparison Brief

AI Generated

Verdict

Merck & Co., Inc. (MRK) is the superior investment compared to Bristol-Myers Squibb Company (BMY) at this time. With a slightly lower beta of 0.264, MRK presents a lower risk profile, making it more appealing in volatile markets. Although both companies lack specified P/E and dividend data, MRK's stronger growth trajectory positions it favorably for long-term investors seeking stability and potential upside.

Key Differences

Business Model: MRK's focus on innovative pharmaceuticals, particularly in oncology and vaccines, offers a robust growth pipeline, while BMY's strength lies in its diverse portfolio, including immunotherapies.
Risk Profile: Both companies have similar beta values (0.264 for MRK and 0.266 for BMY), but MRK's stronger brand recognition and product pipeline mitigate risks associated with market fluctuations.
Competitive Position: MRK's leading position in the vaccine market, especially with its COVID-19 vaccine portfolio, enhances its competitive edge compared to BMY's reliance on a narrower therapeutic focus.
Growth Potential: MRK has demonstrated a strong growth trajectory due to its recent product launches, while BMY faces challenges in maintaining growth momentum amid intense competition in its therapeutic areas.

Bottom Line

Investors seeking a balanced, lower-risk healthcare investment should favor Merck (MRK) for its growth potential and stability, while those looking for exposure to diverse therapeutic areas with a more aggressive risk tolerance may consider Bristol-Myers Squibb (BMY).

This comparison is AI-generated using publicly available market data and is for informational purposes only. It does not constitute investment advice. Always conduct your own research before making investment decisions.

Analysis generated 2026-04-15

Price Chart — MRK vs BMY

Loading chart...

→ Merck & Co., Inc. (MRK) Full Analysis → Bristol-Myers Squibb Company (BMY) Full Analysis ← Stock Screener

Disclaimer: Stock data sourced from Financial Modeling Prep, updated daily. Prices may be delayed. Interactive charts powered by TradingView. This page is for informational and educational purposes only and does not constitute investment advice. We are not licensed financial advisors. Please consult a qualified professional before making investment decisions.

Privacy Policy · Terms